Recent Blogs
Biologics
What a New Farm Bill Means for Biologics and Biosimilars
ACMA
Apr 11, 2023
Career Development
What are the benefits of becoming a Board Certified Medical Affairs Specialist?
ACMA
Jan 13, 2023
Medical Affairs
Medical Affairs Essentials: What is Medical Affairs?
ACMA
Jan 6, 2023
Trending
5 Pharma Industry Trends for 2023
ACMA
Dec 20, 2022
News
What's Next for PhRMA? Pfizer CEO may be in hot water with British Regulators
ACMA
Nov 1, 2022
Trending
4 Medical Affairs Trends for 2023 and Beyond
ACMA
Oct 25, 2022
Biologics
How does the biosimilar market's acceleration affect current and aspiring medical affairs professionals?
ACMA
Oct 20, 2022
Medical Affairs
Medical Information: The Key to Enhancing External Stakeholder Engagement
ACMA
Oct 12, 2022
Medical Affairs
Oncology Medical Science Liaisons: 5 Reasons Why Career Opportunities Are Expanding
ACMA
Sep 14, 2022
Medical Affairs
Leverage Microlearning with Hybrid Medical Affairs Teams
ACMA
Sep 7, 2022
Biologics
Therapeutic Areas Transformed by Biologics: Part 2
ACMA
Aug 31, 2022
Biologics
Therapeutic Areas Transformed by Biologics
ACMA
Aug 17, 2022
Artificial Intelligence
A Guide to Artificial Intelligence for Medical Science Liaisons Part 2
ACMA
Aug 10, 2022
Artificial Intelligence
A Guide to Artificial Intelligence for Medical Science Liaisons
ACMA
Aug 3, 2022
Medical Affairs
3 Facts to Know About the $900 Million Biogen Kickback Settlement
ACMA
Jul 27, 2022
Biologics
The ACMA Answers 7 of Your Questions About Biologics and Biosimilars
ACMA
Jul 20, 2022
Biologics
Biologics and Biosimilars 101
ACMA
Jul 6, 2022
Biologics
Biologics and Biosimilars: The Role of the Medical Science Liaison (MSL)
ACMA
Jun 22, 2022
